Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effect of a Nutritional Product Containing Carob Extract on Carbohydrate Metabolism in Glucose-intolerant Subjects

NCT07420998 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2026-01-26
Last updated
2026-02-19

Condition(s) studied

Prediabetes

Investigational drug(s) / intervention(s)

Experimental ProductControl product

Experimental Product: Participants will consume two doses per day. The product should be taken 30 minutes before the two main meals of the day.

Control product: Participants will consume two daily doses of the placebo product. The product should be taken 30 minutes before the two main meals of the day.

Study summary

Randomized, controlled, double-blind clinical trial with two parallel arms based on the product consumed (experimental product and placebo product) and conducted at a single center, to measure the efficacy of the liquid NUTIFOOD product (nutritional product with carob extract) on carbohydrate metabolism.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Subjects of both sexes aged 18-65 years. * Diagnosis of glucose intolerance according to the American Diabetes Association (at least one of the following criteria): * Impaired fasting glucose (100-125 mg/dl) * Impaired glucose tolerance (oral glucose tolerance test with 2-hour plasma glucose between 140-199 mg/dl) * Glycated hemoglobin between 5.7% and 6.4% * Body mass index between 20-35 kg/m². * Stable dietary habits: no weight gain or loss greater than 5 kg in the last ten weeks. * Volunteers capable of understanding the clinical study and willing to comply with the study procedures and requirements. Exclusion Criteria: * Use of medications that may interfere with glucose metabolism. * Subjects with a history of any type of hepatic or renal disease. * Alcohol consumption greater than 20 g/day. * History of allergic hypersensitivity or poor tolerance to any component of the study products. * Participation in another clinical trial within the three months prior to the study. * Lack of willingness or inability to comply with clinical trial procedures. * Pregnant or breastfeeding women.

Primary outcome measure(s)

  • Glycated Hemoglobin (HbA1c) — Measurements will be performed at baseline, Day 45, and Day 90
    Fasting glycated hemoglobin (HbA1c) will be measured in venous blood samples to assess long-term glycemic control.
  • Area Under the Curve (AUC) of Blood Glucose During Oral Glucose Tolerance Test — This assessment will be conducted at baseline, Day 45, and Day 90.
    The area under the curve (AUC) of blood glucose will be calculated during an oral glucose tolerance test (OGTT) using a 50-g glucose load. Capillary blood glucose levels will be measured at 0, 15, 30, 45, 60, 90, and 120 minutes after glucose ingestion.

Trial sites (1)

FacilityCityRegionStatus
UCAM HiTech, Sport & Health Innovation Hub Murcia Spain Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07420998 on ClinicalTrials.gov ↗ ← All trials in Spain